aTYR PHARMA (ATYR) Total Non-Current Liabilities (2014 - 2016)
aTYR PHARMA's (ATYR) quarterly Total Non-Current Liabilities came in at $114.6 million in Q1 2016, up 92.03% YoY from $59.7 million in Q2 2015, and down 11.26% on a QoQ basis from $129.1 million in Q4 2015.
aTYR PHARMA (ATYR) Total Non-Current Liabilities (2014 - 2016) Analysis & Trends
aTYR PHARMA (ATYR) has 3 years of Total Non-Current Liabilities data on file, last reported at $114.6 million in Q1 2016.
- Quarterly Total Non-Current Liabilities rose 92.03% year-over-year to $114.6 million in Q1 2016, while the trailing twelve-month figure through Mar 2016 was $114.6 million (up 92.03% YoY) and the FY2015 annual result came in at $129.1 million, up 535.2% from the prior year.
- Total Non-Current Liabilities fell to $114.6 million in Q1 2016, from $129.1 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $152.5 million in Q2 2015 to a low of $20.3 million in Q4 2014.
- A 3-year average of $102.8 million and a median of $121.8 million in 2015 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2015 — Total Non-Current Liabilities soared 535.2% — and 2016, when it soared 92.03%.
- Tracing ATYR's Total Non-Current Liabilities over 3 years: stood at $20.3 million in 2014, then soared by 535.2% to $129.1 million in 2015, then slipped by 11.26% to $114.6 million in 2016.
- The last three Total Non-Current Liabilities figures came in at $114.6 million (Q1 2016), $129.1 million (Q4 2015), and $140.8 million (Q3 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 114.57 Mn |
| Dec 31, 2015 | 129.10 Mn |
| Sep 30, 2015 | 140.78 Mn |
| Jun 30, 2015 | 152.49 Mn |
| Mar 31, 2015 | 59.66 Mn |
| Dec 31, 2014 | 20.33 Mn |